3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
3
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Interventions
Rituximab
5
Lenalidomide
3
fludarabine
2
Cyclophosphamide
2
zanubrutinib
1
venetoclax
1
umbralisib
1
ublituximab
1
tisagenlecleucel
1
tazemetostat
1
tafasitamab
1
prednisolone phosphate
1
prednisolone acetate
1
pirtobrutinib
1
obinutuzumab
1
duvelisib
1
axicabtagene ciloleucel
1
Prednisolone
1
Methylprednisolone
1
Bendamustine Hydrochloride
1
Appointments and Schedules
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Lymphoma, Follicular
×
obinutuzumab
×
Clear all
NCT03332017
2026-02-18
ROSEWOOD
BeOne Medicines
Phase 2
Completed
217 enrolled
23 charts
1 FDA